EXHIBIT 99.1 Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development All primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU study Long term 52 week treatment data in landmark, global Phase 2 CSU study demonstrated deepening of response and a favorable safety profile Enrollment continues in Phase 2 PN and EOE studies; Phase 2 AD study to ...